United States securities and exchange commission logo June 1, 2020 Richard Toselli, M.D. Chief Executive Officer InVivo Therapeutics Holdings Corp. One Kendall Square, Suite B14402 Cambridge, MA 02139 Re: InVivo Therapeutics Holdlings Corp. Registration Statement on Form S-1 Filed May 22, 2020 File No. 333-238635 Dear Dr. Toselli: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Paul Fischer at 202-551-3415 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Rosemary Reilly, Esq.